ArticleClinical and experimental immunology2023

Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes.

Urs Christen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.